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Results: Expert networks were more complex with up to 30 
arcs while the data-driven algorithm selected no more than 6 
arcs. Expert and data-driven models were not significantly 
different in discriminative ability (see 95% confidence 
intervals in table). Further, AUCs of all models except expert 
6 were not significantly different from 0.5. Patients with 2-
year survival could be discriminated better as it was 
significantly different from chance in 4 expert models and 
the data-driven model. The data-driven model was 
significantly better than two expert models. 
Conclusions: Discrimination of patients with 2-year survival 
after lung RT is achievable with both methodologies – expert-
based and data-driven models. Reliable discrimination of 
patients with severe dyspnea after RT is not achievable with 
the presented models learned on data of 792 patients. 
Neither expert-based or data-driven models outperform each 
other. Thus, there is dire need for biomarkers predictive of 
radiation-induced dyspnea. For both endpoints, the 
algorithmically derived models are more parsimonious and 
perform as well as the expert-based models or better. 
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Purpose:  Because of the absence of exit dose beyond the 
Bragg peak, protons can improve the radiotherapy physical 
dose distribution. This offers the potential for dose 
escalation to improve local control in anatomic sites and 
histologies where local control of tumor is suboptimal with 
photons. At the same time, the reduction in the normal 
tissue dose/volume profile is anticipated to reduce acute and 
late normal tissue toxicity. The competing technologies 
include intensity modulated photon radiation therapy (IMRT) 
as well as heavier charged particles.  Massachusetts General 
Hospital (MGH) has been a pioneer in the development of 
proton radiation therapy. An overview of the proton radiation 
therapy program at MGH will be provided which will illustrate 
technological progress in proton therapy.  
Materials/Methods:  The initial treatment facility was in the 
Harvard Cyclotron Laboratory, a physics laboratory which was 
modified to accommodate patient treatments. Beam 
generated in a 160 MeV cyclotron was delivered via fixed 
horizontal beams.  In 2001, the program was moved to a 
dedicated clinical facility based at the hospital, the Francis 
H. Burr Proton Therapy Center (FHBPTC). In 2017, an 
additional single room, gantry-based treatment facility will 
open. 
Results:  The FHBPTC has a 230 MeV cyclotron delivering 
beam to two rooms equipped with 360-degree rotational 
gantries and a third clinical room with a two beam-lines, one 
dedicated for treatment of eye tumors and the other for 
stereotactic intracranial radiosurgery/radiotherapy. In 2014, 
we delivered 13, 370 patient treatments at the FHBPTC. 
Currently, one of the two gantries delivers scanned proton 
beams including intensity modulated proton therapy. The 
other gantry delivers passively scattered proton treatments.  
We have U.S. National Cancer Institute funding to support 
clinical trials of intensity modulated proton therapy and to 
study the clinical impact of differences between proton and 
photon dose distributions, to optimize IMPT delivery including 
robust optimization, and to study proton dose perturbations 
caused by the heterogeneous patient and inter- and intra-
factional variations.  We are also active participants in 
ongoing NRG Oncology proton clinical trials. 
Conclusions:  Proton radiation therapy offers a number of 
potential treatment advantages to patients over photons 
related primarily to differences in physical dose distribution; 
clinical gain can be assessed in clinical trials which are 
currently in progress. Rapid changes in technology must be 
considered in designing and conducting clinical trials in this 
area.  
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Tumor-associated macrophages (TAMs) are a phenotypically 
and functionally heterogeneous assortment of monocyte-
derived cells that participate to key processes associated 
with tumor progression, such as angiogenesis, 
immunosuppression, invasion, and metastasis. Increasing 
studies also show that TAMs can either enhance or antagonize 
the antitumor efficacy of cytotoxic chemotherapy, cancer-
cell targeting antibodies, and immunotherapeutic agents, 
depending on the tumor type, macrophage activation state, 
or type of treatment. TAMs can also drive reparative 
mechanisms in tumors after radiotherapy or treatment with 
antiangiogenic drugs. At the meeting, I will discuss the 
biological significance and clinical implications of these 
findings, with an emphasis on novel approaches, based on 
microRNA (miRNA) targeting, to reprogram TAMs into 
immunostimulatory cells. Indeed, we found that efficient 
miRNA depletion in TAMs did not alter their abundance in the 
tumors, but markedly reprogrammed their transcriptomes 
and effector functions from immunosuppressive to 
immunostimulatory. This enhanced cytotoxic T-cell 
infiltration, abated tumor progression, and increased tumor 
responsiveness to immune checkpoint blockade. 
Bioinformatics analysis of TAM transcriptomes identified a 
limited set of miRNAs putatively involved in TAM 
programming, and re-expression of Let-7 in Dicer-deficient 
TAMs was sufficient to rescue TAM’s protumoral phenotype 
and abate tumor CTL infiltration. Collectively, these results 
have identified a mechanism of TAM programming to an 
immunostimulatory phenotype that may be exploited to 
enhance the efficacy of cancer immunotherapies.  
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The aim of radiotherapy is to eradicate cancer, while at the 
same time minimizing the side effects. Although important 
improvements in imaging and radiotherapy techniques have 
enabled better target definitions and radiotherapy delivery, 
normal tissues are always exposed to radiation to some 
degree. Side effects thus still occur, but their variable 
degree, even when corrected for dosimetric characteristics, 
suggests that common genetic variants may play a role.  
However, similar to other human traits, radiosensitivity is 
considered to be a complex polygenic phenotype determined 
by the interaction of multiple loci. 
Identifying these genetic markers will further enable 
precision radiotherapy in which the optimal treatment plan 
will take into account the genetic pre-disposition to toxicity 
(and of the tumour). It should not be assumed that all of the 
phenotypic variation is due to germ line genetic variation, 
but that that epigenetic changes (inherited and acquired) 
could also be important, including variants in mitochondrial 
DNA. 
In response to the lack of success of candidate gene SNP 
studies in small studies, the focus of radiogenomics has 
shifted towards GWAS and big data research within 
international networks (1). At the same time, effort was 
made to establish standardized methods for reporting on 
radiogenomics (2). In recent years, remarkable progress has 
been made in the field of radiogenomics, of which some 
examples are cited. 
Single nucleotide polymorphism genotypes were determined 
in female breast cancer patients from the RAPPER study, 
showing that patients with a high polygenic predisposition to 
breast cancer do not have an increased risk of radiotherapy 
toxicity, but that individual variants may increase risk (3). 
Identifying SNPs in oxidative stress-related genes associated 
with risk of late toxicities in breast cancer patients receiving 
radiation therapy, a variant allele in the base excision repair 
gene XRCC1 was found that could be used in combination 
with additional variants to predict late toxicities (4).  
A GWAS study in 1742 prostate cancer patients treated with 
external beam radiotherapy identified the TANC1 locus (that 
has a role in regenerating damaged muscle) to be of 
significant importance in the development of late radiation-
induced damage (5). It is expected that these and other 
improvements in genotyping together with better 
phenotyping of patients will be incorporated in treatment 
planning, decision support systems and drug development to 
increase the therapeutic ratio of radiotherapy. 
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Combinaison of radiotherapy and immunomodulatory approaches 
is an emerging field. Beside the concurrent inhibition of immune 
checkpoints inhibitors, the association of anti tumor vaccines is a 
way to stimulate specific anti tumor immunity during 
radiotherapy.  Here, we report an extremely effective 
combination of local irradiation (IR) and Shiga Toxin B (STxB)-
based human papillomavirus (HPV) vaccination for the treatment 
